Clinical trial
Antithymocyte Globulin Compared With Supportive Care in Treating Patients With…
NCT00017550 · Genzyme, a Sanofi Company, Industry · Completed
Key facts
| NCT number | NCT00017550 |
|---|---|
| Title | Antithymocyte Globulin Compared With Supportive Care in Treating Patients With Myelodysplastic Syndrome |
| Official title | An Open Label, Prospective, Stratified, Randomized, Controlled, Multi-Center, Phase IIB Study of the Impact of Thymoglobulin Therapy on Transfusion Needs of Patients With Early Myelodysplastic Syndrome (MDS) |
| Lead sponsor | Genzyme, a Sanofi Company, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Myelodysplastic Syndromes |
| Intervention type | Biological |
| Interventions | anti-thymocyte globulin |
| Start date | Sep 1, 2000 |
| Primary completion | Nov 1, 2003 |
| Completion | Nov 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 27, 2021 |
| Countries | Canada, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: